Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 10 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

PPIs and risk for recurrent Clostridium difficile infection among inpatients

The most recent issue of the American Journal of Gastroenterology examines the association between PPI use and risk of recurrent C.difficile infection among inpatients.

News image

Observational studies suggest that proton pump inhibitors (PPIs) are a risk factor for incident Clostridium difficile infection (CDI).

Data also suggest an association between PPIs and recurrent CDI, although large-scale studies focusing solely on hospitalized patients are lacking.

Dr Daniel Freedberg and colleagues therefore performed a retrospective cohort analysis of inpatients with incident CDI to assess receipt of PPIs as a risk factor for CDI recurrence in this population.

Using electronic medical records, the team identified hospitalized adult patients between 2009 and 2012 with incident CDI, defined as a first positive stool test for C. difficile toxin B and who received appropriate treatment.

Electronic records were parsed for clinical factors including receipt of PPIs, other acid suppression, non-CDI antibiotics, and comorbidities.

The team's primary exposure was in-hospital PPIs given concurrently with C. difficile treatment.

The cumulative incidence of CDI recurrence in the cohort was 23%
American Journal of Gastroenterology

Recurrence was defined as a second positive stool test 15–90 days after the initial positive test.

The team found that the C. difficile recurrence rates in the PPI exposed and unexposed groups were compared with the log-rank test.

Multivariable Cox proportional hazards modeling was performed to control for demographics, comorbidities, and other clinical factors.

The research team identified 894 inpatients with incident CDI.

The cumulative incidence of CDI recurrence in the cohort was 23%.

The researchers found that receipt of PPIs concurrent with CDI treatment was not associated with C. difficile recurrence.

Black race, increased age, and increased comorbidities were associated with CDI recurrence.

In light of a higher 90-day mortality seen among those who received PPIs, the team also analyzed the subset of patients who survived to 90 days of follow-up.

The team observed no association between PPIs and CDI recurrence.

The researchers found no association between recurrent CDI and increased duration or dose of PPIs.

Dr Freedberg's team concludes, "Among hospitalized adults with C. difficile, receipt of PPIs concurrent with C. difficile treatment was not associated with CDI recurrence."

"Black race, increased age, and increased comorbidities significantly predicted recurrence. Future studies should test interventions to prevent CDI recurrence among high-risk inpatients."

Am J Gastroenterol 2014: 108: 1794-1801
19 December 2013

Go to top of page Email this page Email this page to a colleague

 09 December 2016 
Use of GI alarm features for colorectal cancer diagnosis
 09 December 2016 
Emergency department use by IBD patients
 09 December 2016 
PPI regimens for upper GI bleeds
 08 December 2016 
Preterm birth in women with IBD
 08 December 2016 
Precision medicine in IBD
 08 December 2016 
Intestinal tuberculosis vs Crohn's disease
 07 December 2016 
Iron deficiency in ulcerative colitis
 07 December 2016 
IBD source of information and patient education
 07 December 2016 
End-of-rotation resident transition and in-hospital mortality
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Quality assurance standards for colonoscopy
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 21 November 2016 
Financial incentives and colorectal cancer screening
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Contraceptives and ulcerative colitis
 15 November 2016 
Physician perspectives on Hep C management
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us